Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), represents a significant medical and economic burden. Although, the launch of the NOACs signifies an important milestone for the treatment and secondary prophylaxis of VTE, there are still some areas of unmet need that remain underserved in this patient population. This report examines current treatment performance against treatment goals in the treatment and secondary prophylaxis of DVT and PE from the perspective of emergency room physicians and hematologists. This report also offers insight from these physicians on existing unmet needs for DVT and PE, while our target product profile conjoint simulator demonstrates how various attributes influence these physicians’ prescribing decisions.
Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered:United States, France, Germany, and United Kingdom.
Primary research: Survey of 60 U.S. and 31 European emergency room physicians and hematologists fielded in May 2018.
Key companies: Bayer, Pfizer, Bristol-Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, and Janssen Pharmaceuticals.
Key drugs: Pradaxa, Xarelto, Eliquis, and Savaysa/Lixiana.